SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer

In this study, the investigators detected the expression of SREBP1 in thyroid cancer tissues, explored the biological functions of SREBP1 in thyroid cancer cells.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Thyroid Cancer Endocrine Gland Neoplasms Endocrine System Diseases Head and Neck Neoplasms Neoplasms Neoplasms by Site Thyroid Diseases Thyroid Neoplasms

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

the Affiliated Cancer Hospital of Xiangya Medical School

Changsha, Hunan, 410078, China

About this study

qRT-PCR and immunohistochemistry were used to detect the expression of SREBP1 in 96 pairs thyroid cancer tissues and the adjacent normal tissues. The following methods, including the MTS, colony-forming assay, flow cytometry and hoechst staining were used to detect the biological function of thyroid cancer cells based on SREBP1 interference or not.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of thyroid cancer Reciving thyroidectomy surgery No experience of radiation therapy Nice treatment compliance and follow-up regularly

Exclusion criteria

Prior history of malignancy ; Radiotherapy history, chemotherapy history; Serious concomitant diseases ; Chronic renal insufficiency and liver dysfunction

Treatment and study plan

pathologic

Other

All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.

Other names: radioiodine

Primary outcomes

progression-free survival

Time frame: average 5 years

disease recurrent of progression

Secondary outcomes

theraputic efficacy

Time frame: average 18 months

According to the ATA guideline, patients were divided into four group, including excellent response (ER),indeterminate response (IDR), biochemical incomplete response (BIR), structural incomplete response (SIR) after surgery and radioiodine treatment.

Sponsors and collaborators

Lead sponsor

People's Hospital of Zhengzhou University

Other

Registry information

Important dates

Study start: 2016
Primary completion: 2017
Study completion: 2018
First posted: Aug 28, 2019
Registry last updated: Aug 28, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed